SCHEMBL599710

SCHEMBL599710

CC(=O)C1CCc2ccccc2C1=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.53
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
PTGS2 P35354 3/20 0.48
KDM4E B2RXH2 3/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 1/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
CYP19A1 P11511 2/20 0.46
CES1 P23141 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29458360 1.00 ACHE (0.53) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL8021509 0.84 ACHE (0.54) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL11599168 0.83 GAA (0.44) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL856747 0.82 ACHE (0.56) ACHESMN1; SMN2KDM4EMAPTALDH1A1
SCHEMBL15912541 0.82 ACHE (0.53) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL578148 0.82 ACHE (0.50) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL30023013 0.82 ACHE (0.50) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL29458361 0.81 HSD17B10 (0.60) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL599658 0.81 HSD17B10 (0.60) ACHENPC1RAB9ASMN1; SMN2PTGS2
SCHEMBL346274 0.80 ACHE (0.51) ACHENPC1RAB9ASMN1; SMN2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10858310-B1 Method for producing isocyanates COVERSTRO DEUTSCHLAND AG (DE) 2020-12-08 US claimed
US-20200361856-A1 METHOD FOR PRODUCING ISOCYANATES COVESTRO DEUTSCHLAND AG (DE) 2020-11-19 US claimed
CN-111250169-A Preparation method and application of high-stability platinum complex catalyst 东莞市晶瑞达硅胶材料科技有限公司 2020-06-09 CN claimed
CN-111051276-A Method for producing isocyanates 科思创德国股份有限公司 2020-04-21 CN claimed
US-20140213690-A1 Titanium Containing Complex and Condensation Reaction Catalysts, Methods for Preparing the Catalysts, and Compositions Containing the Catalysts DOW CORNING CORPORATION (US) 2014-07-31 US claimed
US-20140213750-A1 Hafnium Containing Complex and Condensation Reaction Catalysts, Methods for Preparing the Catalysts, and Compositions Containing the Catalysts DOW CORNING CORPORATION 2014-07-31 US claimed
CN-103781823-A Titanium containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts DOW CORNING 2014-05-07 CN claimed
WO-2013036550-A1 HAFNIUM CONTAINING COMPLEX AND CONDENSATION REACTION CATALYSTS, METHODS FOR PREPARING THE CATALYSTS, AND COMPOSITIONS CONTAINING THE CATALYSTS DOW CORNING CORPORATION (US) 2013-03-14 WO claimed
WO-2013036546-A2 TITANIUM CONTAINING COMPLEX AND CONDENSATION REACTION CATALYSTS, METHODS FOR PREPARING THE CATALYSTS, AND COMPOSITIONS CONTAINING THE CATALYSTS DOW CORNING CORPORATION (US) 2013-03-14 WO claimed
EP-0916697-B1 Hydrosilylation catalysts and silicone compositions using the same SHINETSU CHEMICAL CO (JP) 2002-09-04 EP claimed
US-5583242-A VANADYL COMPLEXES BRISTOL-MYERS SQUIBB COMPANY (US) 1996-12-10 US claimed
EP-0743574-A2 Migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
EP-0743573-A2 Method for obtaining image contrast migration imaging members XEROX CORPORATION (US) 1996-11-20 EP claimed
US-5565491-A FOR TREATMENT OF DISEASES MARKED BY MALIGNANT PROLIFERATION OF B CELLS, SUCH AS LEUKEMIA AND LYMPHOMAS; ANTICARCINOGENIC AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-15 US claimed
US-5563014-A SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT XEROX CORPORATION (US) 1996-10-08 US claimed
US-5514505-A SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE XEROX CORPORATION (US) 1996-05-07 US claimed
EP-0108023-B1 PROCESS FOR THE STABILIZATION OF VINYL CHLORIDE POLYMERS RHONE-POULENC CHIMIE (FR) 1986-12-17 EP claimed
US-4255319-A PHOSPHINE INHIBITION; NONTOXIC; STORAGE STABILITY; MATERIALS HANDLING UNION CARBIDE CORPORATION (US) 1981-03-10 US claimed
US-4123399-A B-DIKETONES, A POLYOL, AND AN ORGANO-METALLIC SALT RHONE-POULENC INDUSTRIES (FR) 1978-10-31 US claimed
US-4123400-A B-DIKETONES, A POLYOL, ORGANO-METALLIC SALTS RHONE-POULENC INDUSTRIES (FR) 1978-10-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200361856-A1 METHOD FOR PRODUCING ISOCYANATES IDH2, ADH5, ADH1C ACHE 929/4885NPC1 1740/4885RAB9A 2812/4885
US-10858310-B1 Method for producing isocyanates IDH2, ADH5, ADH1C ACHE 929/4885NPC1 1740/4885RAB9A 2812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.